UBS Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-285,500
| Closed | -$16.1M | – | 10465 |
|
|
2026
Q1 | $16.1M | Buy |
285,500
+245,100
| +607% | +$14.3M | ﹤0.01% | 2829 |
|
|
2025
Q4 | $2.4M | Buy |
40,400
+27,400
| +211% | +$1.49M | ﹤0.01% | 4805 |
|
|
2025
Q3 | $704K | Sell |
13,000
-1,000
| -7% | -$57.2K | ﹤0.01% | 5839 |
|
|
2025
Q2 | $770K | Buy |
14,000
+13,000
| +1,300% | +$766K | ﹤0.01% | 5663 |
|
|
2025
Q1 | $70.7K | Sell |
1,000
-6,500
| -87% | -$437K | ﹤0.01% | 7320 |
|
|
2024
Q4 | $493K | Sell |
7,500
-38,700
| -84% | -$2.59M | ﹤0.01% | 5849 |
|
|
2024
Q3 | $3.25M | Buy |
46,200
+38,700
| +516% | +$3.23M | ﹤0.01% | 3510 |
|
|
2024
Q2 | $617K | Hold |
7,500
| – | – | ﹤0.01% | 4837 |
|
|
2024
Q1 | $655K | Buy |
+7,500
| New | +$671K | ﹤0.01% | 4974 |
|
|
2023
Q3 | – | Sell |
-9,600
| Closed | -$832K | – | 9479 |
|
|
2023
Q2 | $832K | Buy |
+9,600
| New | +$903K | ﹤0.01% | 4403 |
|
|
2022
Q1 | – | Sell |
-20,000
| Closed | -$1.77M | – | 10272 |
|
|
2021
Q4 | $1.77M | Sell |
20,000
-5,500
| -22% | -$454K | ﹤0.01% | 3840 |
|
|
2021
Q3 | $1.97M | Sell |
25,500
-65,400
| -72% | -$5.16M | ﹤0.01% | 3587 |
|
|
2021
Q2 | $7.58M | Buy |
90,900
+58,400
| +180% | +$4.63M | ﹤0.01% | 2276 |
|
|
2021
Q1 | $2.45M | Buy |
32,500
+22,500
| +225% | +$1.84M | ﹤0.01% | 3355 |
|
|
2020
Q4 | $877K | Hold |
10,000
| – | – | ﹤0.01% | 4117 |
|
|
2020
Q3 | $761K | Buy |
+10,000
| New | +$1.01M | ﹤0.01% | 3840 |
|
|
2020
Q2 | – | Sell |
-33,500
| Closed | -$2.83M | – | 7946 |
|
|
2020
Q1 | $2.83M | Sell |
33,500
-16,500
| -33% | -$1.42M | ﹤0.01% | 2422 |
|
|
2019
Q4 | $4.23M | Sell |
50,000
-25,000
| -33% | -$1.89M | ﹤0.01% | 2759 |
|
|
2019
Q3 | $5.05M | Buy |
75,000
+20,000
| +36% | +$1.54M | ﹤0.01% | 2373 |
|
|
2019
Q2 | $4.71M | Buy |
55,000
+51,400
| +1,428% | +$4.4M | ﹤0.01% | 2373 |
|
|
2019
Q1 | $320K | Buy |
+3,600
| New | +$334K | ﹤0.01% | 4337 |
|
|
2016
Q4 | – | Sell |
-2,500
| Closed | -$231K | – | 7770 |
|
|
2016
Q3 | $231K | Buy |
+2,500
| New | +$235K | ﹤0.01% | 4448 |
|
|
2015
Q2 | – | Sell |
-100
| Closed | -$12K | – | 8492 |
|
|
2015
Q1 | $12K | Hold |
100
| – | – | ﹤0.01% | 7476 |
|
|
2014
Q4 | $9K | Buy |
+100
| New | +$8.32K | ﹤0.01% | 8467 |
|
Other funds holding BMRN
VPC
UBS Group's BMRN Position: Q2 2026 in Review
UBS Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 14% in Q2 2026, selling an estimated $11.5M and leaving 1,286,505 shares worth $73.6M. The position accounts for 0.01% of the portfolio, ranked #1371.
UBS Group first reported a position in BMRN in Q4 2014 and has held it in 47 quarters since. The position peaked at $442M in Q1 2024. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- UBS Group held 1,286,505 shares of BioMarin Pharmaceuticals worth $73.6M as of Q2 2026.
- UBS Group sold 210,347 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $11.5M.
- BioMarin Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1371 holding.
- UBS Group first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- UBS Group's BioMarin Pharmaceuticals position peaked at $442M in Q1 2024.
- 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.